Nevada Clinical Trials
A listing of Nevada clinical trials actively recruiting patient volunteers.
Nevada may be best known for the Las Vegas Strip, but there's plenty to see outside it. Carson City, Reno, and Virginia City all hold their own charms for visitors and residents alike. A vast state with a low population density, it remains the 4th largest producer of gold in the world, even after many Gold Rush "boom towns" have long since been exhausted. As much of the state is dotted with small communities, the best healthcare is centered on larger cities. The Las Vegas area's Sunrise Hospital & Medical Cente is the biggest provider, with more than 640 beds.
Match to Clinical Trials
Match to Clinical Trials
Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, b ...
Characterization of Product Use in Smokers Switching From Cigarettes to a RELX Electronic Nicotine Delivery System
The study will assess product use behaviors, biomarkers of exposure, subjective effects, and safety in smokers who switch to a RELX ENDS over 8-weeks.
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
The purpose of this study is to evaluate the effect of IONIS-AGT-LRx compared to placebo on systolic blood pressure (SBP) from baseline to Study Day 85 in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications and to evaluate the effect of IONIS-AGT-LRx on SBP, diastolic blood pressure (DBP) and plasma angiotensinogen (AGT) at each scheduled visit in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications.
Placebo-controlled Efficacy and Safety Study of GSK3511294 in Participants With Severe Asthma With an Eosinophilic Phenotype
GSK3511294 is being developed as a long-acting (LA) injectable anti-interleukin-5 (anti-IL-5) therapy and is expected to deliver an efficacy and safety profile similar to current anti-IL-5 therapies with a reduced dosing frequency. This study is a multi-center, randomized, placebo-controlled, double-blind, parallel group design and aims to assess the efficacy and safety of GSK3511294 in participants with severe uncontrolled asthma with an eosinophilic phenotype despite standard of care (SoC) tre ...
Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
The objectives of the study are to characterize urea production rates in patients with OTC, characterize the association of rate of ureagenesis and disease severity in OTC patients, characterize the association of rate of ureagenesis and executive and verbal function and characterize the association of rate of ureagenesis and patient-reported functional status.
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and alone, compared with placebo in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73^2.
Differential Target Multiplexed Spinal Cord Stimulation (DTM-SCS®) Real World Outcomes
The UPGRADE registry will capture long-term, real-world outcomes to understand the effect of Differential Target Multiplexed (DTM®) programming in the Spinal Cord Stimulation (SCS) implanted population on the management of chronic pain, primarily on its use for trunk and/or limb pain. The clinical study is sponsored by Celéri Health and is funded through a financial grant from Medtronic's External Research Program. The registry study will be conducted across approximately 30 centers in the Unite ...
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
The main objective of this study is to evaluate the efficacy of SZC as compared to placebo in maintaining normal sK+ in patients with hyperkalemia and metabolic acidosis associated with CKD
CAMPUS - Feasibility Sub-Study
Suicide is the 2nd leading cause of death among college students and suicidal ideation and suicide-related behaviors are a frequent presenting problem at college counseling centers (CCCs), which are overburdened. Studies show that some students respond rapidly to treatment, whereas others require considerably more resources. Evidence-based adaptive treatment strategies (ATSs) are needed to address this heterogeneity in responsivity and complexity. ATSs individualize treatment via decision rules ...
A Study of TAK-510 in Healthy Adults
It is hoped that TAK-510 will help people with symptoms of feeling sick (nausea) or being sick (vomiting). The main aims of the study are to check if healthy adults have side effects from TAK-510 and to check how much TAK-510 they can receive without getting side effects from it. The study will be in 3 parts. Participants will take part in only 1 of the 3 parts of the study. At the first visit, the study doctor will check if each person can take part. For those who can take part, they will be ...
